肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Nature：癌症抗药新发现 防止肿瘤复发有新招

2015-03-31 佚名 生物谷

癌症抗药肿瘤复发
关注

近日，著名国际学术期刊nature在线发表了美国科学家的一项最新研究进展，他们发现癌症靶向治疗药物会引起癌细胞产生分泌信号方面的变化，改变癌细胞生存微环境，最终导致肿瘤复发。这对于临床解决肿瘤抗药性以及癌症复发问题具有重要指导意义。 一直以来，癌症药物抵抗是限制临床应用激酶抑制剂靶向治疗癌症，提高治疗效率的主要因素。研究人员发现在人类和小鼠黑色素瘤以及人类肺腺癌细胞中，靶向BRAF,AL

近日，著名国际学术期刊nature在线发表了美国科学家的一项最新研究进展，他们发现癌症靶向治疗药物会引起癌细胞产生分泌信号方面的变化，改变癌细胞生存微环境，最终导致肿瘤复发。这对于临床解决肿瘤抗药性以及癌症复发问题具有重要指导意义。

一直以来，癌症药物抵抗是限制临床应用激酶抑制剂靶向治疗癌症，提高治疗效率的主要因素。研究人员发现在人类和小鼠黑色素瘤以及人类肺腺癌细胞中，靶向BRAF,ALK和EGFR的激酶抑制剂会诱导细胞产生一个复杂的分泌信号调节网络。这种靶向治疗诱导的分泌信号会刺激产生药物抵抗的癌细胞克隆进一步生长，扩散和转移，并且促进药物敏感性肿瘤细胞存活，最终导致肿瘤的复发。

通过对机制研究发现，在经过激酶抑制剂vemurafenib处理的黑色素瘤细胞中，转录因子FRA1的表达下调会促进这种促肿瘤发展的分泌信号产生。研究人员对产生药物抵抗的黑色素瘤细胞进行原位转录组分析发现有多条信号通路发生激活，其中AKT通路发挥主要作用。通过对RAF和PI3K/AKT/mTOR两条信号通路同时进行阻断能够抑制具有药物抵抗特性的BRAF突变的人类黑色素瘤细胞生长，这表明药物联合治疗或许是对抗肿瘤复发的一种有效策略。
 
综上所述，这项研究表明对药物敏感性癌细胞进行药物治疗抑制癌基因功能会诱导细胞产生大量分泌信号方面的变化，帮助抗药性癌细胞克隆建立合适的肿瘤微环境，但研究人员也发现药物联合治疗对抗药性肿瘤具有明显抑制作用，或许对临床控制肿瘤复发具有重要指导意义。
 
原始出处：

Anna C. Obenauf, Yilong Zou, Andrew L. Ji, Sakari Vanharanta, Weiping Shu, Hubing Shi, Xiangju Kong, Marcus C. Bosenberg,Thomas Wiesner,NealRosen,Roger S. Lo & Joan Massagué.Therapy-induced tumour secretomes promote resistance and tumour progression[J].Nature (2015) doi:10.1038/nature14336

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880567, encodeId=6532188056e01, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 16 20:54:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705580, encodeId=94361e05580e0, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat May 23 08:54:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921111, encodeId=ae671921111ab, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Sep 23 07:54:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24697, encodeId=27482469ea2, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:43:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19923, encodeId=35c819923a1, content=新发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=038a1620818, createdName=lsqlsq, createdTime=Wed Apr 08 06:08:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19133, encodeId=109e191339c, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:48:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-06-16 liye789132251

    #Nat#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1880567, encodeId=6532188056e01, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 16 20:54:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705580, encodeId=94361e05580e0, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat May 23 08:54:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921111, encodeId=ae671921111ab, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Sep 23 07:54:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24697, encodeId=27482469ea2, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:43:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19923, encodeId=35c819923a1, content=新发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=038a1620818, createdName=lsqlsq, createdTime=Wed Apr 08 06:08:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19133, encodeId=109e191339c, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:48:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-05-23 AspirantSuo

    #肿瘤复发#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1880567, encodeId=6532188056e01, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 16 20:54:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705580, encodeId=94361e05580e0, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat May 23 08:54:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921111, encodeId=ae671921111ab, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Sep 23 07:54:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24697, encodeId=27482469ea2, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:43:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19923, encodeId=35c819923a1, content=新发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=038a1620818, createdName=lsqlsq, createdTime=Wed Apr 08 06:08:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19133, encodeId=109e191339c, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:48:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-09-23 vera_1203

    #新发现#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1880567, encodeId=6532188056e01, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 16 20:54:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705580, encodeId=94361e05580e0, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat May 23 08:54:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921111, encodeId=ae671921111ab, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Sep 23 07:54:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24697, encodeId=27482469ea2, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:43:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19923, encodeId=35c819923a1, content=新发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=038a1620818, createdName=lsqlsq, createdTime=Wed Apr 08 06:08:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19133, encodeId=109e191339c, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:48:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-05-24 ljjj1053

    不错，学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1880567, encodeId=6532188056e01, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 16 20:54:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705580, encodeId=94361e05580e0, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat May 23 08:54:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921111, encodeId=ae671921111ab, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Sep 23 07:54:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24697, encodeId=27482469ea2, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:43:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19923, encodeId=35c819923a1, content=新发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=038a1620818, createdName=lsqlsq, createdTime=Wed Apr 08 06:08:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19133, encodeId=109e191339c, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:48:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-04-08 lsqlsq

    新发现

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1880567, encodeId=6532188056e01, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 16 20:54:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705580, encodeId=94361e05580e0, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat May 23 08:54:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921111, encodeId=ae671921111ab, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Sep 23 07:54:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24697, encodeId=27482469ea2, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:43:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19923, encodeId=35c819923a1, content=新发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=038a1620818, createdName=lsqlsq, createdTime=Wed Apr 08 06:08:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19133, encodeId=109e191339c, content=有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:48:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-03-31 cd90

    有意义

    0